DE10351663A1 - Pulverförmige Arzneimittel enthaltend ein Tiotropiumsalz und Salmeterolxinafoat - Google Patents

Pulverförmige Arzneimittel enthaltend ein Tiotropiumsalz und Salmeterolxinafoat Download PDF

Info

Publication number: DE10351663A1
Authority: DE; Germany
Prior art keywords: inhalation; powder; tiotropium; salmeterol; salmeterol xinafoate
Prior art date: 2002-12-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

DE10351663A

Other languages

German (de)

English (en)

Inventor

Hagen Graebner

Mareke Hartig

Peter Sieger

Rainer Soyka

Michael Trunk

Michael Walz

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Boehringer Ingelheim Pharma GmbH and Co KG

Boehringer Ingelheim Pharmaceuticals Inc

Original Assignee

Boehringer Ingelheim Pharma GmbH and Co KG

Boehringer Ingelheim Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-20

Filing date

2003-11-05

Publication date

2004-07-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32404034&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10351663(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-11-05 Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG

2003-11-05 Priority to DE10351663A priority Critical patent/DE10351663A1/de

2004-07-01 Publication of DE10351663A1 publication Critical patent/DE10351663A1/de

Status Withdrawn legal-status Critical Current

Links

GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 title claims abstract description 88
229960005018 salmeterol xinafoate Drugs 0.000 title claims abstract description 43
LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 title claims abstract description 35
239000003814 drug Substances 0.000 title claims abstract description 20
239000000843 powder Substances 0.000 title claims description 126
229940110309 tiotropium Drugs 0.000 title claims description 23
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title abstract description 13
208000006673 asthma Diseases 0.000 title abstract description 8
238000004519 manufacturing process Methods 0.000 claims abstract description 17
208000023504 respiratory system disease Diseases 0.000 claims abstract description 7
239000002775 capsule Substances 0.000 claims description 68
239000000203 mixture Substances 0.000 claims description 53
239000000546 pharmaceutical excipient Substances 0.000 claims description 33
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 17
239000008101 lactose Substances 0.000 claims description 17
238000010586 diagram Methods 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
150000002016 disaccharides Chemical class 0.000 claims description 3
239000008103 glucose Substances 0.000 claims description 3
150000004677 hydrates Chemical class 0.000 claims description 3
238000002844 melting Methods 0.000 claims description 3
230000008018 melting Effects 0.000 claims description 3
150000002772 monosaccharides Chemical class 0.000 claims description 3
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
229930006000 Sucrose Natural products 0.000 claims description 2
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 2
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 2
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 2
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
150000004676 glycans Chemical class 0.000 claims description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
150000002482 oligosaccharides Polymers 0.000 claims description 2
229920001282 polysaccharide Polymers 0.000 claims description 2
239000005017 polysaccharide Substances 0.000 claims description 2
239000005720 sucrose Substances 0.000 claims description 2
150000005846 sugar alcohols Polymers 0.000 claims description 2
150000002500 ions Chemical class 0.000 claims 1
238000000034 method Methods 0.000 abstract description 41
230000008569 process Effects 0.000 abstract description 25
238000002360 preparation method Methods 0.000 abstract description 9
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 58
229960001021 lactose monohydrate Drugs 0.000 description 56
239000002245 particle Substances 0.000 description 51
MQLXPRBEAHBZTK-SEINRUQRSA-M tiotropium bromide hydrate Chemical compound O.[Br-].C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 MQLXPRBEAHBZTK-SEINRUQRSA-M 0.000 description 51
239000004480 active ingredient Substances 0.000 description 45
229960004017 salmeterol Drugs 0.000 description 45
-1 Dextrans) Chemical class 0.000 description 40
239000004698 Polyethylene Substances 0.000 description 34
229920000573 polyethylene Polymers 0.000 description 34
239000000306 component Substances 0.000 description 33
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 32
238000000227 grinding Methods 0.000 description 30
238000002156 mixing Methods 0.000 description 24
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
229960001375 lactose Drugs 0.000 description 16
229910052757 nitrogen Inorganic materials 0.000 description 16
239000000463 material Substances 0.000 description 15
239000000243 solution Substances 0.000 description 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
239000007789 gas Substances 0.000 description 11
239000000047 product Substances 0.000 description 10
229940079593 drug Drugs 0.000 description 9
LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 8
238000009472 formulation Methods 0.000 description 8
239000002904 solvent Substances 0.000 description 8
229960000257 tiotropium bromide Drugs 0.000 description 8
238000010438 heat treatment Methods 0.000 description 7
229920003023 plastic Polymers 0.000 description 7
239000004033 plastic Substances 0.000 description 7
238000009826 distribution Methods 0.000 description 6
238000011049 filling Methods 0.000 description 6
239000008194 pharmaceutical composition Substances 0.000 description 6
239000000126 substance Substances 0.000 description 6
SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 5
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
239000013543 active substance Substances 0.000 description 5
230000008859 change Effects 0.000 description 5
239000013078 crystal Substances 0.000 description 5
238000002425 crystallisation Methods 0.000 description 5
230000008025 crystallization Effects 0.000 description 5
238000011156 evaluation Methods 0.000 description 5
239000002671 adjuvant Substances 0.000 description 4
239000003708 ampul Substances 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
239000000890 drug combination Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000001307 helium Substances 0.000 description 4
229910052734 helium Inorganic materials 0.000 description 4
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 4
239000011261 inert gas Substances 0.000 description 4
238000005259 measurement Methods 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
239000004615 ingredient Substances 0.000 description 3
150000002597 lactoses Chemical class 0.000 description 3
238000007873 sieving Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
239000002585 base Substances 0.000 description 2
230000003454 betamimetic effect Effects 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000000113 differential scanning calorimetry Methods 0.000 description 2
230000007613 environmental effect Effects 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000001746 injection moulding Methods 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
238000011022 operating instruction Methods 0.000 description 2
229920000515 polycarbonate Polymers 0.000 description 2
239000004417 polycarbonate Substances 0.000 description 2
229920000139 polyethylene terephthalate Polymers 0.000 description 2
239000005020 polyethylene terephthalate Substances 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
239000002994 raw material Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000012982 x-ray structure analysis Methods 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
238000004438 BET method Methods 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000808 adrenergic beta-agonist Substances 0.000 description 1
239000002156 adsorbate Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000012824 chemical production Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
229920001903 high density polyethylene Polymers 0.000 description 1
239000004700 high-density polyethylene Substances 0.000 description 1
229940063583 high-density polyethylene Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
239000012907 medicinal substance Substances 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000006082 mold release agent Substances 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
229940120480 nitrogen 30 % Drugs 0.000 description 1
101150101567 pat-2 gene Proteins 0.000 description 1
239000005426 pharmaceutical component Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000011514 reflex Effects 0.000 description 1
239000003507 refrigerant Substances 0.000 description 1
238000005070 sampling Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000007655 standard test method Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000010998 test method Methods 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Emergency Medicine (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DE10351663A 2002-12-20 2003-11-05 Pulverförmige Arzneimittel enthaltend ein Tiotropiumsalz und Salmeterolxinafoat Withdrawn DE10351663A1 (de)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
DE10351663A DE10351663A1 (de)	2002-12-20	2003-11-05	Pulverförmige Arzneimittel enthaltend ein Tiotropiumsalz und Salmeterolxinafoat

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE10259912.2		2002-12-20
DE10259912		2002-12-20
DE10351663A DE10351663A1 (de)	2002-12-20	2003-11-05	Pulverförmige Arzneimittel enthaltend ein Tiotropiumsalz und Salmeterolxinafoat

Publications (1)

Publication Number	Publication Date
DE10351663A1 true DE10351663A1 (de)	2004-07-01

Family

ID=32404034

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE10351663A Withdrawn DE10351663A1 (de)	2002-12-20	2003-11-05	Pulverförmige Arzneimittel enthaltend ein Tiotropiumsalz und Salmeterolxinafoat

Country Status (21)

Country	Link
EP (1)	EP1581198A1 (pl)
JP (1)	JP2006516135A (pl)
KR (1)	KR20050086930A (pl)
CN (1)	CN1728988B (pl)
AU (1)	AU2003288226B2 (pl)
BR (1)	BR0317443A (pl)
CA (1)	CA2510779A1 (pl)
DE (1)	DE10351663A1 (pl)
EA (1)	EA010588B1 (pl)
EC (1)	ECSP055855A (pl)
FR (1)	FR2848849B1 (pl)
HR (1)	HRP20050570A2 (pl)
IT (1)	ITMI20032473A1 (pl)
MX (1)	MXPA05006519A (pl)
NO (1)	NO20053548L (pl)
NZ (1)	NZ541303A (pl)
PL (1)	PL376231A1 (pl)
RS (1)	RS20050484A (pl)
UA (1)	UA83813C2 (pl)
WO (1)	WO2004058233A1 (pl)
ZA (1)	ZA200503692B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP4342426B2 (ja) *	2004-11-24	2009-10-14	科研製薬株式会社	イトラコナゾール経口投与用製剤
CA2617897A1 (en) *	2005-08-06	2007-02-15	Boehringer Ingelheim International Gmbh	Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol
KR101395881B1 (ko) *	2005-12-19	2014-05-21	시코르, 인크.	브롬화 티오트로피움의 신규한 형태 및 이의 제조 방법
CN102838599A (zh)	2006-05-04	2012-12-26	贝林格尔.英格海姆国际有限公司	多晶型
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
DE102007036411A1 (de)	2007-07-20	2009-02-12	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pulverinhalator
UY31235A1 (es) *	2007-07-21	2009-03-02		Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru)	2008-12-23	2015-12-30	Бёрингер Ингельхайм Интернациональ Гмбх	Солевые формы органического соединения
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
NZ599298A (en)	2009-11-27	2014-11-28	Boehringer Ingelheim Int	Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (en)	2010-05-05	2011-11-10	Boehringer Ingelheim International Gmbh	Combination therapy
NZ603319A (en)	2010-06-24	2015-04-24	Boehringer Ingelheim Int	Diabetes therapy
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CA2841552C (en)	2011-07-15	2020-06-23	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US20130303554A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en)	2012-05-14	2020-07-29	Boehringer Ingelheim International GmbH	Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es)	2014-02-28	2023-10-09	Boehringer Ingelheim Int	Uso médico de un inhibidor de DPP-4
KR101748796B1 (ko) *	2015-09-30	2017-06-19	한미약품 주식회사	활성성분의 전달량이 향상된 흡입용 캡슐제
WO2017211979A1 (en)	2016-06-10	2017-12-14	Boehringer Ingelheim International Gmbh	Combinations of linagliptin and metformin
EP3880251B1 (en) *	2018-11-13	2025-04-09	Cocrystal Pharma, Inc.	Formulations of influenza therapeutics

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1056974C (zh) *	1992-02-11	2000-10-04	格拉克索公司	适宜于微粒化的药物材料的制备方法
WO1993016031A1 (en) *	1992-02-11	1993-08-19	Glaxo Group Limited	Benzenedimethanol derivative suitable for micronisation
GB9313650D0 (en) *	1993-07-01	1993-08-18	Glaxo Group Ltd	Method and apparatus for the formation of particles
DE19921693A1 (de) *	1999-05-12	2000-11-16	Boehringer Ingelheim Pharma	Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
UA75375C2 (en) *	2000-10-12	2006-04-17	Boehringer Ingelheim Pharma	Method for producing powdery preparations for inhaling
DE10056104A1 (de) *	2000-11-13	2002-05-23	Boehringer Ingelheim Pharma	Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
DE10104367A1 (de) *	2001-02-01	2002-08-08	Boehringer Ingelheim Pharma	Betamimetika enthaltende Arzneimittelkompositionen mit geringeren Nebenwirkungen
DE10130371A1 (de) *	2001-06-23	2003-01-02	Boehringer Ingelheim Pharma	Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
WO2003013633A1 (en) *	2001-08-09	2003-02-20	Glaxo Group Limited	Inhalation device with a pharmaceutical composition
EP1429768B1 (de) *	2001-09-14	2016-11-16	Boehringer Ingelheim Pharma GmbH & Co.KG	Neue arzneimittel zur inhalation

2003
- 2003-04-12 UA UAA200507088A patent/UA83813C2/ru unknown
- 2003-11-05 DE DE10351663A patent/DE10351663A1/de not_active Withdrawn
- 2003-12-04 MX MXPA05006519A patent/MXPA05006519A/es unknown
- 2003-12-04 PL PL03376231A patent/PL376231A1/pl not_active Application Discontinuation
- 2003-12-04 CN CN2003801069216A patent/CN1728988B/zh not_active Expired - Fee Related
- 2003-12-04 JP JP2004562686A patent/JP2006516135A/ja active Pending
- 2003-12-04 WO PCT/EP2003/013691 patent/WO2004058233A1/de not_active Ceased
- 2003-12-04 CA CA002510779A patent/CA2510779A1/en not_active Abandoned
- 2003-12-04 NZ NZ541303A patent/NZ541303A/en unknown
- 2003-12-04 KR KR1020057011668A patent/KR20050086930A/ko not_active Ceased
- 2003-12-04 BR BR0317443-3A patent/BR0317443A/pt not_active IP Right Cessation
- 2003-12-04 EA EA200500902A patent/EA010588B1/ru not_active IP Right Cessation
- 2003-12-04 EP EP03780120A patent/EP1581198A1/de not_active Withdrawn
- 2003-12-04 HR HR20050570A patent/HRP20050570A2/xx not_active Application Discontinuation
- 2003-12-04 RS YUP-2005/0484A patent/RS20050484A/sr unknown
- 2003-12-04 AU AU2003288226A patent/AU2003288226B2/en not_active Ceased
- 2003-12-16 IT IT002473A patent/ITMI20032473A1/it unknown
- 2003-12-19 FR FR0315082A patent/FR2848849B1/fr not_active Expired - Fee Related
2005
- 2005-05-09 ZA ZA200503692A patent/ZA200503692B/en unknown
- 2005-06-15 EC EC2005005855A patent/ECSP055855A/es unknown
- 2005-07-19 NO NO20053548A patent/NO20053548L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2003288226B2 (en)	2010-01-07
NO20053548L (no)	2005-09-02
MXPA05006519A (es)	2005-08-26
PL376231A1 (pl)	2005-12-27
WO2004058233A1 (de)	2004-07-15
CN1728988B (zh)	2010-04-28
ZA200503692B (en)	2006-10-25
HRP20050570A2 (en)	2006-07-31
JP2006516135A (ja)	2006-06-22
BR0317443A (pt)	2005-11-16
FR2848849A1 (fr)	2004-06-25
CA2510779A1 (en)	2004-07-15
CN1728988A (zh)	2006-02-01
UA83813C2 (ru)	2008-08-26
ECSP055855A (es)	2005-11-22
EA200500902A1 (ru)	2006-02-24
NZ541303A (en)	2008-11-28
EA010588B1 (ru)	2008-10-30
ITMI20032473A1 (it)	2004-06-21
EP1581198A1 (de)	2005-10-05
RS20050484A (sr)	2007-11-15
KR20050086930A (ko)	2005-08-30
AU2003288226A1 (en)	2004-07-22
FR2848849B1 (fr)	2007-01-05

Legal Events

Date	Code	Title	Description
2011-02-03	8141	Disposal/no request for examination

Publication	Publication Date	Title
EP1292281B1 (de)	2004-09-08	Neue tiotropium-haltige inhalationspulver
EP1581198A1 (de)	2005-10-05	Pulverformige arzneimittel zur inhalation enthaltend ein tiotropiumsalz und salmeterolxinafoat
EP1379220B1 (de)	2004-12-29	Inhalationskapseln
EP2182933B1 (de)	2016-09-07	Neue pulverförmige arzneimittel enthaltend tiotropium und salmeterol sowie laktose als hilfsstoff
EP1785422B1 (de)	2016-11-16	Kristallines Mikronisat des Tiotropiumbromids
EP1326585B1 (de)	2006-03-08	Verfahren zur herstellung von pulverformulierungen
EP1283036B1 (de)	2008-01-02	Multidosis-Trockenpulverinhalator mit Pulverreservoir
DE10141377A1 (de)	2003-03-13	Aufstreuverfahren zur Herstellung von Pulverformulierungen
EP1424996B1 (de)	2005-04-27	Verfahren zur herstellung von inhalationspulvern
EP1567135B1 (de)	2008-07-23	Tiotropiumhaltige pulverformulierung für die inhalation
DE60308497T2 (de)	2007-02-22	Pulverzubereitungen zur inhalation
EP2298415B1 (de)	2013-06-12	Tiotropiumbromid-Mikronisat
EP1646365B1 (de)	2009-01-14	Pulverformulierungen für die inhalation enthaltend ein neues anticholinergikum
DE10338407A1 (de)	2005-03-17	Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
DE10138022A1 (de)	2003-02-20	Verfahren zur Herstellung von Pulverformulierungen